Medical/Pharmaceuticals

The New Era Biotechnology deepens cooperation between China and Belarus in the Great Stone China Belarus Industrial Park (CBIP)

MINSK, Belarus, Dec. 10, 2021 /PRNewswire/ -- As an enterprise in CBIP, the New Era Biotechnology Co., Ltd. participated in the fourth edition of the China International Import Expo (CIIE) which opened inShanghai on November 5, 2021.       Located in Minsk, capital of the Republic of Belarus a...

2021-12-10 23:38 5238

Qiming's Portfolio Company CANbridge Pharmaceuticals Lists on Main Board of HKEx

SHANGHAI, Dec. 10, 2021 /PRNewswire/ -- Qiming Venture Partners' portfolio company CANbridge Pharmaceuticals (SEHK: 1228), a leadingChina-based global rare disease-focused biopharmaceutical company, today listed on the main board of Hong Kong Stock Exchange. The issue price isHK$ 12.18 per share,...

2021-12-10 15:15 5574

CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies

CASTRES, France, Dec. 10, 2021 /PRNewswire/ -- Today, the final findings of the CONTROL study1 were presented at the 2021 San Antonio Breast Cancer Symposium (SABCS). Results suggest that providing a prophylactic anti-diarrhoea medical treatment or applying a dose escalation schedule of neratinib...

2021-12-10 15:11 3332

Research shows Lianhua Qingwen capsules conferred preventive effects on those exposed to COVID-19

SHIJIAZHUANG, China, Dec. 10, 2021 /PRNewswire/ -- "Lianhua Qingwen capsules conferred preventive effects on those exposed to COVID-19", claimed an article titled "Efficacy and Safety of Lianhuaqingwen Capsules for the Prevention of Coronavirus Disease 2019: A Prospective Open-Label Controlled Tr...

2021-12-10 12:49 4408

Össur hf: CEO Retirement and Succession Plan

STOCKHOLM, Dec. 10, 2021 /PRNewswire/ -- Jon Sigurdsson to retire after 26 years as Össur President and CEO,Sveinn Sölvason appointed President and CEO successor Jon Sigurdsson has decided to retire from his position as President and CEO of Össur. The Board of Directors has appointed Össur CFO,S...

2021-12-10 07:03 2917

Cordis Names George Adams, MD as Chief Medical Officer

MIAMI LAKES, Fla., Dec. 9, 2021 /PRNewswire/ -- Cordis, a global cardiovascular technology company, today announcedGeorge Adams, MD, MHS, MBA, FACC, FSCAI as Chief Medical Officer, furthering the organization's mission to differentiate itself as a technological leader and value-based global medic...

2021-12-09 23:00 4749

AnchorDx Achieves Academic Breakthrough with Deep Methylation Representation Learning Research Paper Accepted by 36th AAAI Conference

GUANGZHOU, China, Dec. 9, 2021 /PRNewswire/ -- AnchorDx, a world-leading developer of cancer screening and early detection solutions, was accepted on December 1, 2021, to present its "Noninvasive Lung Cancer Early Detection via Deep Methylation Representation Learning" research paper (DeepMeth) at...

2021-12-09 22:00 3466

The innovative software "CAAS vFFR" by Pie Medical Imaging for the non-invasive physiological assessment of intermediate coronary lesions is the subject of FAST III, a multicenter European clinical trial which will investigate the effectiveness of the vessel Fractional Flow Reserve (vFFR) guided revascularization as compared to conventional FFR guided revascularization

MAASTRICHT, Netherlands, Dec. 9, 2021 /PRNewswire/ --  Pie Medical Imaging ("PMI"), a global leader in cardiac imaging, part of the Esaote Group, today announced the beginning of FASTIII, a multicenter randomized clinical trial which willinvestigate the use of angiography-based vessel fractional ...

2021-12-09 21:00 3768

Seegene Rapidly Introduces New PCR Test that Identifies the Omicron Variant, its Stealth Version, and all VOCs in a single tube

SEOUL, South Korea, Dec. 9, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530),  South Korea's leading molecular diagnostics company, today unveiled another series of diagnostic test that detects the ever-changing COVID-19 variant landscape. The Novaplex™ SARS-CoV-2 Variants VII assay addresses Omicron...

2021-12-09 20:18 2933

Sciwind Biosciences Completes Enrollment in Phase 2 Clinical Trial of XW003 in Type 2 Diabetes Patients

HANGZHOU, China and SAN FRANCISCO, Dec. 9, 2021 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the completion of patient enrollment in its Phase 2 clin...

2021-12-09 20:00 3455

Another clean interim safety review of RhoVac's clinical phase IIb study in prostate cancer

HELSINKI, Dec. 9, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today onDecember 9th, 2021, that its Data & Safety Monitoring Committee (DSMC) has conducted a planned interim safety review of its clinical phase IIb trial in prostate cancer, known as ...

2021-12-09 16:58 1691

Proximie Partners with Jhpiego in New Initiative to Improve Obstetric Surgical Care

- The Obstetric Safe Surgery (OSS) Project in Kenya is funded by Johnson & Johnson and to date has been implemented by Jhpiego as the lead organization, in collaboration with County and National Ministries of Health and professional associations. - To support implementation moving forward, Proxi...

2021-12-09 15:00 5556

Posters Highlighting clinical data of KN026 presented at SABCS 2021

SUZHOU, China, Dec. 9, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced that two posters highlighting data from two clinicalstudies of the anti-HER2 bispecific antibody KN026 were presented at the 44th San...

2021-12-09 12:20 3031

Lunit Named to the 2021 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups

SEOUL, South Korea, Dec. 9, 2021 /PRNewswire/ -- CB Insights today named Lunit to its third annual Digital Health 150 , which showcases the 150 most promising private digital healt...

2021-12-09 11:24 3047

Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021

- Trial met both primary endpoints demonstrating statistically significant and clinically meaningful extension of progression free survival (PFS) as monotherapy vs. standard of care (SoC) endocrine therapy in overall population and estrogen receptor mutation (mESR1) population - In the overall p...

2021-12-09 08:38 3737

Servatus raises $7.5 million to advance autoimmune therapies with its microbial biotherapeutics clinical programs

* Servatus has raised $7.5 million in an oversubscribed capital raise, with strong support from sophisticated shareholders * Funds raised will underpin Servatus' live microbial and engineered protein biotherapeutics drug development * Two Phase 1/2 clinical trials to launch shortly in Queens...

2021-12-09 07:35 3755

Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China

The approval marks the first locally-discovered and approved SARS-CoV-2 target-specific treatment inChina, through a randomized, double-blind and placebo-controlled trial Brii Bio is also seeking U.S. FDA Emergency Use Authorization for the amubarvimab/romlusevimab combination DURHAM, N.C. and ...

2021-12-09 06:10 4521

CRI Online: China's Fangchenggang City Hosts 2021 IMICF

FANGCHENGGANG, China, Dec. 8, 2021 /PRNewswire/ -- A news reported by CRI Online: On December 6, the 2021 International Medical Innovation Cooperation Forum was held in Fangchenggang City,Guangxi Province online and offline.  The scene of...

2021-12-08 21:17 5217

Donisi Health Takes Home First Place in the Prestigious Innovations in Cardiovascular Intervention Competition

MedTech Startup Focused on Home Monitoring for Patients with Congestive Heart Failure and Other Chronic Diseases Wins the 2021 ICI Pitch Competition and $200,000 Award TEL AVIV, Israel, Dec. 8, 2021 /PRNewswire/ -- Donisi Health (Donisi) prevailed in this year's ICI In...

2021-12-08 21:01 2854

Treadwell Therapeutics Announces A Presentation at the 2021 SABCS Annual Meeting Featuring a Clinical Trial Update on CFI-402257, a Best-in-Class TTK inhibitor

NEW YORK and HONG KONG, Dec. 8, 2021 /PRNewswire/ -- Treadwell Therapeutics, today announced a presentation for the Company's CFI-402257 program, an oral, best-in-class TTK inhibitor, at the 2021 San Antonio Breast Cancer Symposium (SABCS) being held from December 7-10, 2021.  This presentation w...

2021-12-08 20:00 3500
1 ... 362363364365366367368 ... 381